Vorinostat

Drug Profile

Vorinostat

Alternative Names: L-001079038; MK 0683; SAHA; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Zolinza

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Columbia University; Memorial Sloan-Kettering Cancer Center
  • Developer Banyu; Bayer; Columbia University; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Research Center; Groupe Francophone des Myelodysplasies; H. Lee Moffitt Cancer Center and Research Institute; Indiana University; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Center for Tumor Diseases; Roswell Park Cancer Institute; Stanford University; Takeda; University Hospital Heidelberg; University of North Carolina at Chapel Hill; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Mesothelioma; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T cell lymphoma
  • Phase II Acute myeloid leukaemia; B cell lymphoma; Breast cancer; Glioma; HIV-1 infections; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Phase I/II Leukaemia; Lymphoma; Solid tumours
  • Phase I Glioblastoma; Gliosarcoma
  • No development reported Brain metastases; Colorectal cancer; Hodgkin's disease
  • Discontinued Gynaecological cancer; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Sickle cell anaemia

Most Recent Events

  • 16 Mar 2018 Phase-I clinical trials in Glioblastoma (Combination therapy, Newly diagnosed) in USA (PO) (NCT03426891)
  • 16 Mar 2018 Phase-I clinical trials in Gliosarcoma (Combination therapy, Newly diagnosed) in USA (PO) (NCT03426891)
  • 31 Dec 2017 Indiana University, Bayer, Mearck and Millennium Pharmaceuticals completes a phase I/II trial in Acute myeloid leukaemia (Combination therapy) in USA (IV) (NCT01534260)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top